🇺🇸 FDA
Patent

US 11981897

Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

granted A61PA61P21/00A61P21/02

Quick answer

US patent 11981897 (Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression) held by Ionis Pharmaceuticals, Inc. expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P21/00, A61P21/02